ライフサイエンスコーパス: consolidation chemotherapy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 not after each of 4 cycles of induction and consolidation chemotherapy.

2 d the benefit of cyclosporine (CsA) added to consolidation chemotherapy.

3 er ATRA maintenance or observation following consolidation chemotherapy.

4 who had been receiving radiation therapy and consolidation chemotherapy.

5 l [CI], 18% to 42%) in patients receiving no consolidation chemotherapy, 22% (95% CI, 17% to 28%) in

6 evaluated molecular response after induction/consolidation chemotherapy according to standardized met

7 The patient continued with consolidation chemotherapy and an autologous bone marrow

8 vant chemotherapy with intrathecal thiotepa, consolidation chemotherapy, and autologous stem-cell res

9 erapy, autologous stem-cell transplantation, consolidation chemotherapy, and maintenance with interfe

10 rred infrequently, monitoring after post-HDT consolidation chemotherapy appears warranted.

11 ogeneic SCT, autologous transplantation, and consolidation chemotherapy are considered of equivalent

12 arm, and patients in this arm received less consolidation chemotherapy as a result of higher inducti

13 s bone marrow transplantation with intensive consolidation chemotherapy as treatments for children wi

14 Induction and consolidation chemotherapy, as well as radiation dose, c

15 The value of administering consolidation chemotherapy before human leukocyte antige

16 rs administered after induction and possibly consolidation chemotherapy can shorten the duration of n

17 ompared randomized assignment with intensive consolidation chemotherapy (CC) or autologous bone marro

18 and safety of bortezomib in combination with consolidation chemotherapy consisting of intermediate-do

19 stable disease received two 21-day cycles of consolidation chemotherapy consisting of paclitaxel 200

20 Both groups received consolidation chemotherapy consisting of vincristine and

21 ith high-dose DAT and the addition of CsA to consolidation chemotherapy did not prolong the durations

22 Phase II studies of induction or consolidation chemotherapy have also shown promise but t

23 sting the addition of GO to induction and/or consolidation chemotherapy in untreated younger patients

24 patients in first remission after intensive consolidation chemotherapy might prevent relapse.

25 tanea tarda was admitted to the hospital for consolidation chemotherapy of his leukemia.

26 of 254 patients who completed induction and consolidation chemotherapy on CALGB 9720 were randomly a

27 e/cytarabine combination, followed by either consolidation chemotherapy or allogeneic stem cell trans

28 est in evaluating the role of maintenance or consolidation chemotherapy or both.

29 induced CR (P =.018) and at first test after consolidation chemotherapy (P =.037).

30 After consolidation chemotherapy, patients with NQ exceeding 1

31 2 weeks after chemoradiation, two cycles of consolidation chemotherapy separated by 3 weeks were giv

32 2 and Total Therapy 3 that applied post-HDT consolidation chemotherapy (suggesting possible post-HDT

33 Remitting patients received one course of consolidation chemotherapy that included DNR with or wit

34 ection, postoperative radiation therapy, and consolidation chemotherapy (three courses of cyclophosph

35 The most common adverse reaction during consolidation chemotherapy was grade III neutropenia in

36 nts with AML receiving uniform induction and consolidation chemotherapy, we demonstrate that the time

37 first complete remission after induction and consolidation chemotherapy were randomly assigned to no

38 Of 37 children who received consolidation chemotherapy with ABMR, 15 are free of dis

39 as a slightly higher death rate in CR during consolidation chemotherapy with ADE (9%) than with DAT (

40 remission (CR) received up to two courses of consolidation chemotherapy with cytarabine 2 gm/m(2) on

41 Responding patients received consolidation chemotherapy with DNR pharmacokinetics per

42 Postremission consolidation chemotherapy with either placebo or PEG-rH

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。